852180-76-8

Basic information

• Product Name: [4-(2-MORPHOLIN-4-YLETHOXY)PHENYL]METHANOL
• Synonyms: 4-[2-(MORPHOLIN-4-YL)ETHOXY]BENZYL ALCOHOL;[4-(2-MORPHOLIN-4-YLETHOXY)PHENYL]METHANOL;4-[2-(Morpholin-4-yl)ethoxy]benzyl alcohol 97%;4-[2-(Morpholin-4-yl)ethoxy]benzylalcohol97%
• CAS NO: 852180-76-8
• Molecular Formula: C₁₃H₁₉NO₃
• Molecular Weight: 237.29
• Mol File: 852180-76-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 0°C
• Boiling Point: 0°C
• Flash Point: 0°C
• Appearance: /
• Density: 1.138 g/cm³
• Vapor Pressure: 2.86E-07mmHg at 25°C
• Refractive Index: 1.542
• CAS DataBase Reference: [4-(2-MORPHOLIN-4-YLETHOXY)PHENYL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(2-MORPHOLIN-4-YLETHOXY)PHENYL]METHANOL(852180-76-8)
• EPA Substance Registry System: [4-(2-MORPHOLIN-4-YLETHOXY)PHENYL]METHANOL(852180-76-8)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 852180-76-8(Hazardous Substances Data)

Usage

General Description

[4-(2-MORPHOLIN-4-YLETHOXY)PHENYL]METHANOL is a chemical compound with the molecular formula C16H19NO3. It is a benzene derivative with a morpholine ring attached to the fourth carbon of the phenyl ring and a methanol group attached to the benzene ring. [4-(2-MORPHOLIN-4-YLETHOXY)PHENYL]METHANOL is often used in organic synthesis as a reagent or intermediate for the production of pharmaceuticals, agrochemicals, and other fine chemicals. It has potential applications in medicinal chemistry due to its ability to modify the activity of certain biological molecules. Additionally, it may be used as a building block in the synthesis of various bioactive compounds.

InChI:InChI=1/C13H19NO3/c15-11-12-1-3-13(4-2-12)17-10-7-14-5-8-16-9-6-14/h1-4,15H,5-11H2

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 82625-45-4 4-(2-morpholin-4-yl-ethoxy)-benzaldehyde 

Downstream Products

• 1335047-84-1 1-[4-(2-morpholinoethoxy)benzyl]naphthalen-2-ol 
• 1323402-47-6 3-(4-(4-(2-morpholinoethoxy)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 1261297-30-6 cyclopropyl{4-[4-(2-morpholin-4-yl-ethoxy)benzyloxy]phenyl}methanone 
• 859393-07-0 3,7-dimethoxy-10-[4-(2-morpholin-4-yl-ethoxy)-benzyl]-10H-benzo[4,5]thieno[3,2-b]indole 
• 859393-05-8 7-methoxy-10-[4-(2-morpholin-4-yl-ethoxy)-benzyl]-10H-benzo[4,5]thieno[3,2-b]indole 
• 212771-34-1 4-(2-(chloromethyl-phenoxy)-ethyl)-morpholine 

Relevant articles and documents

Compound and preparation method and application thereof

The invention relates to the field of medicinal chemistry and pharmacotherapeutics, in particular to a bazedoxifene analog compound and a preparation method thereof, application of the bazedoxifene analog compound in a GP130 small molecule inhibitor and t

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The invention provides compounds of Formula (I) : wherein R1 is hydrogen, OH, halo, -CN, -NO2, -N=0, -NHOQ2, -OQ2, -SOQ2, -SO2Q2, -SON(Q2)2, - SO2N(Q2)2, -N(Q2)2, -C(O)OQ2, -C(O)Q2, -C(O)N(Q2)2, -C(=NQ2)NQ2, -NQ2C(=NQ2)NQ2, - C(O)N(Q2)(OQ2), -N(Q2)C(O)-Q2, -N(Q2)C(O)N(Q2)2, -N(Q2)C(O)O-Q2, -N(Q2)SO2Q2, -N(Q2)SOQ2, aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, or heteroaryl ring, each aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, and heteroaryl ring optionally including 1-3 substituents independently selected Q3; R2 and R3 are each independently hydrogen, OH, oxo, aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, optionally substituted with 1-3 of Q1 or Q2; X is a branched or straight C1-12 aliphatic chain wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, -CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, - O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, -SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-; G and G1 are each independently a branched or straight C1-2 aliphatic chain, or heterocycloalkyl, wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, - CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, -O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, - SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-, and pharmaceutically acceptable salts, solvates or prodaigs thereof, as well as methods of treating estrogen receptor mediated diseases and disorders using the compounds of Formula (I).

Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy)phenyl cyclopropyl methanols

A series of [4-(aryloxy)phenyl]cyclopropyl methanones were synthesized by reaction of different benzyl alcohols with 4-chloro-4′-fluorobutyrophenone in DMF in the presence of NaH/TBAB. The methanones were further reduced to respective methanols. The antitubercular activity of these compounds was evaluated in vitro against Mycobacterium tuberculosis H37Rv. Compounds 19, 21, 35, 36 and 37 have shown minimum inhibitory concentration (MIC) of 3.12 μg/mL, while compounds 14, 25 and 18 have shown MIC of 1.56 μg/mL and 0.78 μg/mL respectively. One of the compounds, cyclopropyl-4-[4-(2-piperidin-1- yl-ethoxy)benzyloxy]phenyl}methanol (36) showed 98% killing of intracellular bacilli in mouse bone marrow derived macrophages and was active against MDR, XDR and rifampicin clinical isolates resistant strains with MIC 12.5 μg/mL. Compound 36 was orally active in vivo in mice against M. tuberculosis H37Rv with an increase in MST by 6 days with 1 log reduction in the bacillary density in lungs as compared to control on 30th day after infection.